[血小板与败血症患者多重有机衰竭的关联]
Emiliano Bocanegra-Alegría1, Edgar Bravo-Santibáñez1, Claudia Berenice Márquez-Torres2
1Instituto Mexicano del Seguro Social, Centro Médico Nacional Bajío, Unidad Médica de Alta Especialidad Hospital de Especialidades No. 1, Servicio de Terapia Intensiva. León, Guanajuato, México.
Revista medica del Instituto Mexicano del Seguro Social
|March 3, 2026
概括
败血症患者血小板数量较低表明多器官衰竭 (MOF) 的风险较高. 这项研究强调了血小板缺血作为重症监护室败血症病例预后不佳的重要指标.
科学领域:
- 关键护理医学 关键护理医学
- 血液学 血液学 血液学
- 病理生理学 病理生理学
背景情况:
- 败血症的特征是炎症和凝血,血小板异常,如血小板缺血是常见的.
- 微循环血栓的形成和增加的消耗是血清炎症中血小板数量下降的主要驱动因素.
- 之前的研究表明,血小板水平降低与患者治疗结果较差之间存在联系.
研究的目的:
- 调查血小板计数和多器官衰竭 (MOF) 在被诊断为败血症的重症监护病房 (ICU) 患者的发展之间的关联.
主要方法:
- 在接受ICU治疗的成年败血症患者中进行了一项回顾性,横截面的研究.
- 血清血小板水平在ICU入院后进行测量.
- 统计分析包括曼-惠特尼U测试,ROC曲线分析和二进制物流回归.
主要成果:
- 分析了93名败血症患者,46.2%的患者经历了MOF.
- 与没有MOF的患者相比,MOF患者的血小板数量显著降低 (149 × 10^9/L) (217.5 × 10^9/L).
- 血小板计数截止值为174 × 10 ^ 9 / L预测了MOF (AUC0.710),较低的血小板与MOF (OR 8.53) 有关. 然而,在多变量分析中,急性损伤成为MOF最强的独立预测因素 (OR 27.8).
结论:
- 血小板数量下降是ICU内的败血症患者多器官衰竭相关的危险因素.
- 败血症患者的血小板缺血需要密切监测,因为它与MOF有关.
- 虽然血小板计数是一个重要的因素,但急性损伤是这个人群中MOF的更强有力的预测因素.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Structure and Function of Platelets
7.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
7.1K
Introduction to Hemostasis
14.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.2K
Formation of the Platelet Plug
6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K


